secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001129928-26-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed
--------------------------------------------------------------------------------

- Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).
- Plans to meet with FDA mid-April to align on single-arm SCAC registrational study; believes <100 subjects may be sufficient for approval.
- GOBLET Cohort 5 (PDAC) enrollment stopped at ~20 patients per arm; data to inform future PDAC strategy.
- Sufficient cash on hand to execute near-term milestones, avoiding immediate material dilution.
- GOBLET data support platform approach in GI cancers; company will follow existing Cohort 5 patients for survival data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000006/0001129928-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000006/oncy-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer